NanoConversion Technologies, Inc. Competitors

Kongsberg NanoAvionics is a small-satellite mission integrator focused on building new-generation satellite buses ranging from 10 to 500 kg and on providing end-to-end mission services. NanoAvionics is setting the industry benchmark for small satellites, delivering the right balance between cost, performance, and reliability, which enables a wide range of satellite applications. Since 2014, hundreds of customers from over 35 countries have trusted NanoAvionics to deliver space solutions that maximize mission success and accelerate return on satellite investment. As a subsidiary of KONGSBERG, we bring together agility and innovation with the heritage and robustness of one of the most trusted technology groups. NanoAvionics is ISO 9001 and ISO 14001 certified, following high-standard quality and environmental management procedures.

Nanochem Solutions, Inc. (NCS) is a chemical engineering company designed to develop, and optimize processes for the production, transformation, and utilization of chemical ingredients. Our team of chemical engineers, analytical chemists, and operators apply their knowledge and skills to various industries, including pharmaceuticals, nutraceuticals, food & beverage, petrochemicals, agriculture, detergents, environmental protection, and more. We specialize in developing new materials and products, improving existing processes, while ensuring safety and sustainability in the production and use of chemicals. The nutraceutical division offers carefully sourced , high-quality nutritional ingredients and excipients utilized in a wide range of liquid and powder processing capabilities that include, but are not limited to: Spray Drying Particle Encapsulations Fully Reacted Actives Beadlets (via extrusion and active layering) NCS is dedicated to delivering exceptional results while working closely with our customers to create standout nutraceutical dosage forms.

Nanospectra Biosciences is a medical device company pioneering a patient-centric use of nanomedicine for selective thermal ablation. AuroLase, the company's lead product for the ablation of prostate cancer tissue, is the first and only ultra-focal tissue ablation therapy designed to maximize treatment efficacy while minimizing side effects typically associated with surgery, radiation, and traditional focal therapies. Implementing a multi-prong growth strategy, Nanospectra is focusing on clinical advancements, exclusive partnering agreements and ongoing research and development. Nanospectra’s technology development has been funded to date by a series of grants, private equity investments and corporate partnerships.